LP-008

N/A

Report date: 2022/03/17 17:28:14

Base Information

Drug NameLP-008

Drug Alias Name重组人源化抗PD-L1单克隆抗体/人TGF-β融合蛋白LP-008

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionProgrammed death-ligand 1 blockersTransforming growth factor beta 2 inhibitors

TargetsProgrammed death-ligand 1Transforming growth factor beta 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesLepu Biopharma Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLepu Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A